As the threat of the COVID-19 pandemic emerged in early 2019, Cardinal Health worked to proactively identify diagnostic solutions as they became available. With confirmed human-to-human spread and the potential impact of the virus starting to come in to focus, Cardinal Health teamed with suppliers across multiple platforms to ensure broad access to diagnostic products for our customers.
On February 2, 2020, the United States Center for Disease Control received the first Emergency Use Authorization for its rRT-PCR SARS-CoV-2 assay . Cardinal Health initially focused on rRT-PCR assays due to their high level of sensitivity and specificity in aiding in diagnosing the presence of the live virus. However, broad access to PCR testing in the clinical lab community is limited by the need for necessary equipment for RNA excitation as well as thermocyclers. As Cardinal Health vetted potential suppliers in this category, it was important to consider the supplier’s established ability to provide products to the standard of Cardinal Health’s customers, as well as a stable and reliable supply chain.
On March 16, 2020, Cardinal Health began distribution of the Quidel Lyra Assay, which would go on to be validated on multiple extraction platforms and thermocyclers, bringing access to high quality COVID-19 diagnostic products to a large number of clinical lab customers. As Quidel continued to innovate, the Lyra Direct Assay was launched, reducing the workflow of RNA extraction, lowering turn around time, and providing broader clinical access to this solution. To date, Cardinal Health has provided over 500,000 tests to more than 40 customers across the United States.
Click here for more information on the Quidel Lyra offerings from Cardinal Health.